Biopharmaceuticals
Censa Pharmaceuticals is clinical-stage pharmaceutical company developing CNSA-001, an oral therapy for phenylketonuria (PKU) patients across all ages and disease severities. PKU is a rare, inherited metabolic disorder that is caused by mutations in the phenylalanine hydroxylase (PAH) gene. Patients with mutations in the PAH gene inefficiently metabolize phenylalanine (Phe) leading to elevated blood levels of Phe and neurocognitive impairment.
Jonathan Reis, Ph.D.
Nice Insight/That’s Nice
89 Fifth AvenueFifth FloorNew YorkNY 10003-3020
New York – San Diego – ChicagoLondon – Frankfurt – Shanghai
Nice Insight is the market research division of That’s Nice LLC, the leading marketing agency serving life sciences.